KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Net Income (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Net Income for 11 consecutive years, with -$163.2 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 106.46% to -$163.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$614.1 million through Dec 2025, down 50.53% year-over-year, with the annual reading at -$614.1 million for FY2025, 50.53% down from the prior year.
  • Net Income hit -$163.2 million in Q4 2025 for CRISPR Therapeutics AG, down from -$106.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $759.3 million in Q2 2021 to a low of -$514.5 million in Q4 2021.
  • Historically, Net Income has averaged -$91.2 million across 5 years, with a median of -$114.9 million in 2021.
  • Biggest YoY gain for Net Income was 1053.18% in 2021; the steepest drop was 306.54% in 2021.
  • Year by year, Net Income stood at -$514.5 million in 2021, then soared by 78.05% to -$112.9 million in 2022, then skyrocketed by 179.17% to $89.4 million in 2023, then crashed by 188.41% to -$79.0 million in 2024, then tumbled by 106.46% to -$163.2 million in 2025.
  • Business Quant data shows Net Income for CRSP at -$163.2 million in Q4 2025, -$106.4 million in Q3 2025, and -$208.5 million in Q2 2025.